Zacks Investment Research upgraded shares of Immune Pharmaceuticals, Inc. (IMNP) from N/A to OUTPERFORM on March 10, 2014, with a target price of $9.00.
We are initiating coverage of Immune Pharmaceuticals, Inc. (OTC: IMNP) with a Buy rating and a $9.00 price target. Immune is developing a first-in-class monoclonal antibody targeting eotaxin-1, a chemokine that has been implicated in a number of inflammatory diseases, including inflammatory bowel disease (IBD), bullous pemphigoid (BP) and severe asthma. The lead candidate bertilimumab is in Phase 2 trials for both IBD and BP. Biomarker based patient selection is a key differentiator for Bertilimumab and is expected to maximize its clinical value and reduce development risks.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Immune Pharmaceuticals, Inc. (IMNP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment